NeuroImmunology
8.2K views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE from Alzheimer's Disease R&D Review
Scoop.it!

Molecular Neurodegeneration | Full text | Immunotherapy for Alzheimer's disease: hoops and hurdles

Alzheimer’s disease (AD) is the most common form of dementia, afflicting more than 30 million people worldwide. Currently, there is no cure or way to prevent this devastating disease.

Via Krishan Maggon
Gilbert C FAURE's insight:
Abstract

.... Extracellular plaques, containing various forms of amyloid-β protein (Aβ), and intracellular neurofibrillary tangles (NFTs), composed of hyper-phosphorylated tau protein, are two major pathological hallmarks of the AD brain. Aggregation, deposition, and N-terminal modification of Aβ protein and tau phosphorylation and aggregation are thought to precede the onset of cognitive decline, which is better correlated with tangle formation and neuron loss. Active and passive vaccines against various forms of Aβ have shown promise in pre-clinical animal models. However, translating these results safely and effectively into humans has been challenging. Recent clinical trials showed little or no cognitive efficacy, possibly due to the fact that the aforementioned neurodegenerative processes most likely pre-existed in the patients well before the start of immunotherapy. Efforts are now underway to treat individuals at risk for AD prior to or in the earliest stages of cognitive decline with the hope of preventing or delaying the onset of the disease. In addition, efforts to immunize against tau and other AD-related targets are underway.

Krishan Maggon 's curator insight, November 2, 2014 1:56 AM

Review

Immunotherapy for Alzheimer’s disease: hoops and hurdles

Cynthia A Lemere

Correspondence: Cynthia A Lemere clemere@partners.org

Author Affiliations

Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, NRB 636F, 77 Avenue Louis Pasteur, Boston 02115, MA, USA

Molecular Neurodegeneration 2013, 8:36  doi:10.1186/1750-1326-8-36


The electronic version of this article is the complete one and can be found online at:http://www.molecularneurodegeneration.com/content/8/1/36


Received:3 July 2013Accepted:23 September 2013Published:22 October 2013

© 2013 Lemere; licensee BioMed Central Ltd. 

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Scooped by Gilbert C FAURE from Alzheimer's Disease R&D Review
Scoop.it!

Crystal structure reveals conservation of amyloid-ß conformation recognized by 3D6 following humanization to bapineuzumab

Crystal structure reveals conservation of amyloid-ß conformation recognized by 3D6 following humanization to bapineuzumab | NeuroImmunology | Scoop.it
Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer’s disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the preferred epitope or conformation of amyloid-β to target for treatment, and the mechanism of action underlying immunotherapy. Bapineuzumab (humanized 3D6), a neo-epitope specific antibody recognizing amyloid-β1-5 with strong preference for an exposed Asp residue at the N-terminus of the peptide, has undergone advanced clinical testing for treatment of AD.

 

Here we report the crystal structure of a recombinant Fab fragment of 3D6 in complex with amyloid-β1-7 solved at 2.0 Å resolution. The N-terminus of amyloid-β is bound to 3D6 as a 310 helix. The amino-terminal Asp residue is buried deepest in the antibody binding pocket, with the Cβ atom of residue 6 visible at the entrance to the binding pocket near the surface of the antibody. We further evaluate homology model based predictions used to guide humanization of 3D6 to bapineuzumab, with actual structure of the Fab. The structure of the Fab:amyloid-β complex validates design of the humanized antibody, and confirms the amyloid-β epitope recognized by 3D6 as previously mapped by ELISA.

Conclusions

The conformation of amyloid-β antigen recognized by 3D6 is novel and distinct from other antibodies recognizing N-terminal epitopes. Our result provides the first report demonstrating structural conservation of antigen contact residues, and conformation of antigen recognized, between the parent murine antibody and its humanized version.

 

Figure 1. Overview of the structure of 3D6 fab with Aβ1-7 peptide (pdb identifier 4ONF). A) Side view showing alpha-carbon backbone traces of the molecules. Heavy chain is shown in cyan, light chain in blue and Aβ peptide in yellow/orange. B) 3D6 with Aβ1-7 view from above the molecule. Peptide is shown in stick representation with oxygens colored red, nitrogens in blue and carbons orange. Fab in surface representation colored white with the exception of CDRs contacting the peptide. CDR H1 is shown in red, H2 blue, H3 green, L1 magenta and L3 cyan. Only CDRs contacting the peptide are colored. CDRs, complementarity determining regions; pdb, protein data base.


Via Krishan Maggon
Krishan Maggon 's curator insight, September 20, 2014 4:47 PM

open access

 

Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab

Hadar Feinberg2, José W Saldanha5, Linnea Diep1, Amita Goel1, Angela Widom3,Geertruida M Veldman6, William I Weis2, Dale Schenk4 and Guriqbal S Basi1*

*Corresponding author: Guriqbal S Basi gur1balbasi@gmail.com

Author Affiliations

1Elan Pharmaceuticals, Inc. 300 Technology Sq., Cambridge, MA 02139, USA

2Departments of Structural Biology and of Molecular & Cellular Physiology, 299 Campus Drive, Stanford University School of Medicine, Stanford, CA 94305, USA

3Pfizer, Cambridge, MA, USA

4Prothena Biosciences, Inc., 650 Gateway Blvd., San Francisco, CA 94080, USA

5National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK

6Abbvie Bioresearch Center, Worcester, MA, USA

For all author emails, please log on.

Alzheimer's Research & Therapy 2014, 6:31  doi:10.1186/alzrt261